Olema net loss widens 44.29% to $63.2 million in Q2 FY26 - OLMA News | RalliesOlema net loss widens 44.29% to $63.2 million in Q2 FY26
O
OLMA• Q2 loss widens as expenses rise
- Olema Pharmaceuticals posted a Q2 net loss of $63.2 million, widening from $43.8 million a year earlier.
- GAAP R&D expense rose to $57.8 million from $43.9 million, on higher clinical development, research, and personnel-related costs.
- GAAP G&A expense climbed to $9.4 million from $4 million, driven by higher corporate investment, stock-based compensation, and professional fees.
- Cash, cash equivalents, and marketable securities totaled $461.1 million at June 30, 2026.
Pipeline update and upcoming milestones
- Olema said it completed OPERA-01 Phase 3 enrollment.
- Top-line data are expected in Q1 2027.
- A Bayer collaboration is set to start OP-3136-plus-darolutamide enrollment in Q4 2026.
NTCO
•
